What is the pipeline for future medications for obesity?

Studied

Review of current and pipeline obesity medicines, emphasizing GLP-1 and combinations with GIP, glucagon, or amylin. It does not report one intervention, comparator, or follow-up period.

Who / model

Literature review with no enrolled population, species, or sample size reported in the abstract.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The review reports mean weight loss of 15-17% with semaglutide 2.4 mg and up to 22.5% in phase 3 tirzepatide obesity trials. CagriSema and retatrutide had reached phase 3; early data were described as potentially exceeding tirzepatide, not as a direct comparative result.

Limits

The abstract gives no review-selection methods, study counts, or formal quality assessment. Its statement that early pipeline data may exceed tirzepatide is not a head-to-head finding, so methodological quality remains unassessed.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary